N/A
N=36
Acute Effect of MMT Peel Powder on Glycemic Response, Satiety, and Food Intake in Adults at Risk for Type 2 Diabetes
At Risk of Type 2 Diabetes Mellitus
Bottom Line
View on ClinicalTrials.gov: NCT05298111 ↗Enrolled (actual)
36
Serious AEs
—
Results posted
Aug 2024
Primary outcome: Primary: Blood Glucose Levels — 5.6; 5.7; 6.7; 7.7 mmol/L — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Formulation 3 (Other); Control (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Universiti Sultan Zainal Abidin
- Primary completion
- Nov 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Blood Glucose Levels |
5.6; 5.7; 6.7; 7.7; 7.4; 8.2 | <0.001 sig |
| SECONDARY Perceived Satiety (Area Under the Curve) |
200.5; 277; 912; 822.5; 231; 329 | < 0.001 sig |
| SECONDARY Food Intake |
219.3; 225.2; 74.1; 75.3; 74.3; 77.2 | < 0.001 sig |
| SECONDARY Calories Intake |
1796; 1893 | 0.001 sig |
Summary
Open-label, randomised, placebo-controlled, crossover study with two intervention arms. The study was conducted in 30 respondents and the primary objective is to show an improved glycemic response after Melon Manis Terengganu (MMT) peel powder consumption in people at risk of type 2 diabetes.
Eligibility Criteria
Inclusion Criteria
- Modified Finnish Type 2 Diabetes Risk Assessment Tool (FINDRISC) score ≥ 4
- Capillary fasting blood glucose (FBG) < 7.0 mmol/L
- Malaysian
- Live, work or study in Kuala Nerus, Terengganu
- Both gender
- Age 18 to 59 years old
- Non-smoker
- Those taking supplement agree to undergo washout period of one week
Exclusion Criteria
- Had clinical history of type 2 diabetes mellitus (T2DM)
- Capillary FBG ≥ 7.0 mmol/L
- Take oral antidiabetic agents
- Participate in other weight management programme or interventional research
- On a prescribed medical diet
- GI illnesses or conditions
- Allergy or sensitivity to study products
- Pregnant, currently breastfeeding, or planning to become pregnant
- On dietary restrictions
- Smoker
Data sourced from ClinicalTrials.gov (NCT05298111). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.